Small Molecules Capability

Australia is ideally positioned to be a major player in the global Pharma ecosystem where risk-averse companies are looking to in-licence assets that have demonstrated development potential.

Therefore, to enhance the progression of early stage discoveries through to preclinical development, TIA has formed a Small Molecules capability which is an integrated capability network of National Research Infrastructure across Australia. These facilities are committed to provide high quality research infrastructure to support leading‑edge research and to boost innovation in Australia.

 

Capabilities​/ Services offered

  • National compound management and logistics facility for small molecule compound libraries and natural product extract and fraction libraries.

  • Researcher access to critical infrastructure and expertise for flexible, reproducible
    and cost effect sample handling to support national screening initiatives.

  • Provides storage and management of the national open access compound collection, GRIDD's NatureBank collection and numerous proprietary compound collections.

Capabilities/Services offered  >

Compounds Australia

105_19_ACRF_COMBINATION_RGB_trimmed_sml.
105_19_ACRF_COMBINATION_RGB_trimmed_sml.
 
Capabilities/Services offered  >

Australian Translational Medicinal Chemistry Facility 

Capabilities​/ Services offered

  • Optimisation of screening hits and lead compounds

  • Mechanism- or substrate-based design and synthesis of enzyme inhibitors

  • Advice on drug discovery strategy including literature/patent searching and creating intellectual property

  • Custom synthesis of known/novel compounds

  • Other chemistry needs eg. targeted drug delivery and novel linker design and synthesis

ATMCF_latest logo_Dec 2020.png
ATMCF_latest logo_Dec 2020.png
Capabilities/Services offered  >

Centre for Drug Candidate Optimisation

Capabilities​/ Services offered

  • Integrated in vitro studies to assess ADME

  • Physicochemical profiling and characterisation

  • Drug metabolism, metabolite identification, and assessment of metabolic drug interactions

  • Assessment of permeability and binding properties

  • Small animal pharmacokinetic studies to determine clearance mechanisms and oral bioavailability

  • Discovery stage bioanalysis by LC MS/MS

CDCO.jpg
CDCO.jpg
 
Capabilities/Services offered  >

Centre for Integrated Preclinical Drug Development

Capabilities​/ Services offered

  • Preclinical efficacy studies in rodent models of human disease

  • New rodent models of human disease in response to collaborator need

  • Training of research students in related techniques in response to academic collaborator request

Capabilities/Services offered  >

TetraQ

Capabilities​/ Services offered

  • Pharmacokinetics and screening toxicology studies in rodents to support preclinical development 

  • GLP toxicology and toxicokinetics studies in rodents to enable first-in-human clinical studies

TetraQ.tif
TetraQ.tif